Annual report pursuant to Section 13 and 15(d)

CollabRx Acquisition (Details)

v2.4.0.6
CollabRx Acquisition (Details) (USD $)
 0 Months Ended 12 Months Ended
Jul. 12, 2012
Mar. 31, 2013
Advisor
Business Acquisition [Line Items]    
Business acquisition effective date Jul. 12, 2012  
Acquisition agreement date Jun. 29, 2012  
Percentage of interests acquired (in hundredths) 100.00%  
Number of shares issuable to acquire business (in shares) 236,433  
Shares issued specified as percentage of total shares outstanding (in hundredths) 14.00%  
Interest rate on promissory note (in hundredths) 0.28%  
RSUs and options granted as "inducement grants" to newly hired management (in shares)   368,417
Vesting period of equity awards   4 years
Noncompetition period   3 years
Stockholders Agreement Period of transfer restrictions and voting provisions   2 years
Assets acquired [Abstract]    
Cash $ 476,000  
AP and accrueds (333,000)  
Deferred tax liability (664,000)  
Goodwill 603,000  
Total Acquired Assets, net 1,732,000  
Purchase Price summary [Abstract]    
Common Stock Consideration 932,000  
Promissory Note Assumed 500,000  
Loan Note Payable Assumed 300,000  
Total Purchase Price 1,732,000  
Number of clinical and scientific advisors   50
"Big data" opportunity value   300,000,000,000
Tax benefit recognized   83,000
Developed Technology [Member]
    
Assets acquired [Abstract]    
Intangible assets 720,000  
Customer Relationships [Member]
    
Assets acquired [Abstract]    
Intangible assets 433,000  
Trade Name [Member]
    
Assets acquired [Abstract]    
Intangible assets 346,000  
Non Compete Agreements [Member]
    
Assets acquired [Abstract]    
Intangible assets $ 151,000  
Restricted Stock Units (RSUs) [Member]
    
Business Acquisition [Line Items]    
Aggregate RSUs forfeited (in shares)   215,475